3 Point Bio LLC

Boxford, MA

UEI
ZJVEA4HE2FJ3
CAGE
82FP7
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
4 Dana Rd, Boxford, MA 01921, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant subawards

Prime recipient Prime award Amount Awarded
The Broad Institute, Inc. Innovative technologies to transform antibiotic discovery. U19AI142780 $380,000
The Broad Institute, Inc. Innovative Technologies to Transform Antibiotic Discovery U19AI142780 $337,845

Similar vendors

Vendor Location Primary NAICS
Debiopharm International SA UEI YN12U3HMB8W7 Lausanne, VD —
Fimbrion Therapeutics Inc. UEI N9RQX3G4EH54 St. Louis, MO 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Curza Inc. UEI VGN5BH7K3DN9 Salt Lake City, UT —
Quercus Molecular Design, LLC UEI ZHH5N3KV48A5 Avon, CT 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Nubad LLC UEI ENA5G1N2MWP4 Greer, SC 541380 Testing Laboratories and Services

About the company

3 Point Bio LLC is a for-profit limited liability company that provides research and development services related to pharmaceuticals and therapeutics. Based on past federal grants as a subawardee, 3 Point Bio has focused its efforts on developing new antibiotic compounds and sensitization strategies to treat drug resistant bacteria, particularly Gram negative pathogens like Pseudomonas aeruginosa.

As a subawardee on federal grants from The Broad Institute, 3 Point Bio has led medicinal chemistry efforts, ADME/PK studies, and interpretation of animal studies to advance compounds from hit to lead stage. More specifically, they have helped make go/no-go decisions on molecular scaffolds, optimized combinations for testing, guided co-administration studies, and advanced 1-3 hits per grant to late lead stage with in vivo proof of concept against priority Gram negative bacteria. Additionally, 3 Point Bio has advised on therapeutic discovery and development for tuberculosis, including early scaffold selection, design of non-GLP and GLP toxicology studies, and IND-enabling studies. Their role has been to provide industry guidance and direction to academic prime grantees in order to progress compounds through preclinical pipelines.

Quick answers

Is 3 Point Bio LLC registered in SAM.gov?

Yes. 3 Point Bio LLC's SAM.gov registration is active through March 16, 2027.

On GovTribe

See 3 Point Bio LLC's full federal record

  • Similar vendors